Abivax Reports Business Updates and First Half 2026 Financial Results

Abivax, a biotechnology firm, announced key leadership changes and financial results for the first half of 2026. Chris Rabbat will replace Fabio Cataldi as Chief Medical Officer, while Tim Kelly joins as Chief Technical Officer. These appointments are strategic for Abivax's progression toward commercializing obefazimod, their lead therapeutic candidate.

Financially, Abivax reported cash and equivalents totalling €402.4 million as of June 30, 2026. Following a public offering, they secured additional net proceeds of €767.1 million, extending the cash runway into the fourth quarter of 2029. The recent buy-back of royalty certificates strengthened their debt-free position.

Operating expenses increased, with R&D costs rising to €107.9 million, driven by clinical trial progression. General and administrative expenses also saw a rise to €30.4 million, attributed to increased personnel and consulting fees. Despite these expenses, Abivax is preparing for potential commercialization pivotal to its growth strategy.